Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8439746 | European Journal of Cancer | 2018 | 8 Pages |
Abstract
Implementation of the 8th AJCC staging edition will presumably not have major impact on the total number of Dutch pT1b patients. Consequently, the number of patients eligible for SLNB would roughly remain similar. In terms of SLNB positivity, the selection of high-risk pT1 melanoma patients is likely to improve. In addition, the 8th edition criteria for pT1 melanoma seem more workable for pathologists.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
D. Verver, W.J. Louwman, S. KoljenoviÄ, C. Verhoef, D.J. Grünhagen, A.C.J. van Akkooi,